Other Events ·
PDS Biotechnology Corporation received a deficiency letter from Nasdaq on July 30, 2026, notifying the company that…
PDSBPDS Biotechnology Corp
PDS Biotechnology Corporation received a deficiency letter from Nasdaq on July 30, 2026, notifying the company that its common stock has traded below the $1.00 minimum bid price requirement for the last 30 consecutive business days. The company was granted an 180-day compliance period ending January 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to meet this requirement may result in delisting, though the stock continues to trade under symbol PDSB on the Nasdaq Capital Market. The company stated it may consider options such as a reverse stock split to regain compliance but provided no assurance of success. PDS Biotechnology Corporation operates in the biotechnology industry, focusing on the development of therapeutic products.